DE50304603D1 - Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze - Google Patents

Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Info

Publication number
DE50304603D1
DE50304603D1 DE50304603T DE50304603T DE50304603D1 DE 50304603 D1 DE50304603 D1 DE 50304603D1 DE 50304603 T DE50304603 T DE 50304603T DE 50304603 T DE50304603 T DE 50304603T DE 50304603 D1 DE50304603 D1 DE 50304603D1
Authority
DE
Germany
Prior art keywords
feline
virus
oncovires
leucose
cat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50304603T
Other languages
German (de)
English (en)
Inventor
Claas Junghans
Matthias Schroff
Christiane Juhls
Detlef Oswald
Prof Hans Lutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologen AG
Original Assignee
Mologen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen AG filed Critical Mologen AG
Priority to DE50304603T priority Critical patent/DE50304603D1/de
Application granted granted Critical
Publication of DE50304603D1 publication Critical patent/DE50304603D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE50304603T 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze Expired - Lifetime DE50304603D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE50304603T DE50304603D1 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10244863 2002-09-23
PCT/DE2003/003179 WO2004028562A2 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
DE50304603T DE50304603D1 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Publications (1)

Publication Number Publication Date
DE50304603D1 true DE50304603D1 (de) 2006-09-21

Family

ID=32038184

Family Applications (2)

Application Number Title Priority Date Filing Date
DE50304603T Expired - Lifetime DE50304603D1 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
DE10393824T Expired - Fee Related DE10393824D2 (de) 2002-09-23 2003-09-19 Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE10393824T Expired - Fee Related DE10393824D2 (de) 2002-09-23 2003-09-19 Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze

Country Status (9)

Country Link
US (1) US7915035B2 (enExample)
EP (1) EP1553977B1 (enExample)
JP (1) JP4411213B2 (enExample)
AT (1) ATE335507T1 (enExample)
AU (1) AU2003281917A1 (enExample)
DE (2) DE50304603D1 (enExample)
DK (1) DK1553977T3 (enExample)
ES (1) ES2270120T3 (enExample)
WO (1) WO2004028562A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
EP3706789A1 (en) 2017-11-06 2020-09-16 Intervet International B.V. Feline calicivirus vaccine
CA3080427A1 (en) * 2017-11-06 2019-05-09 Intervet International B.V. Feline leukemia virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
WO2003031470A2 (de) * 2001-10-02 2003-04-17 Mologen Ag Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose

Also Published As

Publication number Publication date
EP1553977B1 (de) 2006-08-09
WO2004028562A2 (de) 2004-04-08
JP2006511211A (ja) 2006-04-06
ATE335507T1 (de) 2006-09-15
US20060240034A1 (en) 2006-10-26
JP4411213B2 (ja) 2010-02-10
DK1553977T3 (da) 2006-11-27
AU2003281917A1 (en) 2004-04-19
ES2270120T3 (es) 2007-04-01
DE10393824D2 (de) 2005-08-11
EP1553977A2 (de) 2005-07-20
AU2003281917A8 (en) 2004-04-19
US7915035B2 (en) 2011-03-29
WO2004028562A3 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
WO2001064835A8 (en) Novel nucleic acids and polypeptides
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
NO20052149D0 (no) Vaksine.
ATE461710T1 (de) Nipah-virus-impfstoffe
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
DE50304603D1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
DK1290160T3 (da) Humane Pellino-polypeptider
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
ATE380557T1 (de) E. coli vakzin zur protektion von geflügel gegen colibazillose
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
DK0778894T3 (da) Vaccine mod infektiös felin peritonitis
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
DK1196607T3 (da) Antibakterielt chlamysin B-protein, gen kodende derfor samt ekspressionssystem
CY1105629T1 (el) Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
CY1107371T1 (el) Αυξηση της θυμοσινης στην γενετικη ανοσοποιηση
ATE473013T1 (de) Induzierte immunantwort gegen den katzen- immunschwäche-virus
WO2004101607A3 (en) Comparative ligand mapping from mhc class i positive cells
PA8619101A1 (es) Polipeptidos recombinantes para diagnosticar la infeccion con el trypanosoma cruzi
WO2006110881A3 (en) Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition